Cathrine C. Ramberg

Avhandlingen er tilgjengelig her! / The doctoral thesis is available here!

Auditoriet er åpent for publikum, men disputasen vil også bli strømmet. Opptaket av disputasen vil være tilgjengelig i et døgn.
The auditorium is open to the public. The defense will still be streamed. A recording of the disputation will be available for 24 hours.


Prøveforelesning over oppgitt emne starter kl. 10.15 / The trial lecture starts at 10.15
Tittel/Title: "Biomarkers for the risk of venous thrombosis".
Prøveforelesningen strømmes her / The trial lecture will be streamed here

Disputasen starter kl. 12.15 / The defense starts at 12.15
Disputasen strømmes her / The defense will be streamed here

 
Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis

Venous thromboembolism (VTE) is the formation of a blood clot in the deep veins of the legs or in the lungs. Negatively charged procoagulant phospholipids (PPL) are vital to efficient coagulation activation and found expressed on the surface of extracellular vesicles and activated platelets.

In this thesis, we have developed a method to measure the effect of PPL on coagulation by modifying a FXa-dependent clotting assay. We further used the assay to investigate the association between plasma PPL activity and the risk of VTE in a population-based nested case-control study (Tromsø Study) and the STAtins Reduce Thrombophilia trial.

We observed an inverse association between PPL clotting time and the risk of future VTE in the nested case-control study, supporting an important role of PPL in the pathogenesis of VTE. Further, rosuvastatin treatment caused a substantial decrease in plasma PPL activity in subjects with a history of VTE, which may partly explain the previously reported reduced risk of VTE recurrence by statin treatment.

Veiledere/ Supervisors:
Hovedveileder/Main supervisor:
Professor John-Bjarne Hansen, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.
Biveiledere/supervisors:
Postdoktor Omri Snir, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.
Dr.med Ph.d. Timofey Sovershaev, Institutt for medisinsk biologi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.

Bedømmelseskomité/Defensecomitee:
Professor Pierre Morange, Laboratoire d'Hématologie, Marseille, France – 1. opponent.
Førsteamanuensis Carola Elisabeth Henriksson, UiO – 2. opponent.
Professor Trond Flægstad, IKM, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité.

Disputasleder/ Leader of defense:
Professor Rolv-Ole Lindsetmo, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet